Menu
1 min read · estimated
APPROVED USE
What FDA approved
Patients aged 2 years and older with advanced or metastatic RET fusion-positive thyroid cancer requiring systemic therapy and refractory to radioactive iodine when it is appropriate.
LAMPGEN ANALYSIS
Why it matters
The action converted the RET fusion-positive thyroid indication to traditional approval and included younger patients.
What research teams should watch
Record iodine treatment history or why it is inappropriate and distinguish RET fusion testing from RET mutation testing.
PRIMARY RECORDS